趙瑩珺 副研究員 副研究員，博士 E-mail: zhaoyingjun@fudan.edu.cn

　　2001年獲武漢大學理學學士學位，2005年獲復旦大學病原生物學碩士學位，2010年獲復旦大學病原生物學博士學位，2005-2013年在上海市腫瘤研究所癌基因及相關基因國家重點實驗室工作，從事腫瘤基因組學及細胞信號轉導通路等方面的研究工作。2013年10月任職于復旦大學生物醫學研究院和復旦大學附屬腫瘤醫院腫瘤研究所，副研究員。

研究領域：

　　肝癌基因組學，表觀遺傳學
　　從事腫瘤相關基因功能及細胞信號轉導和腫瘤功能基因組學等研究，研究microRNA及lncRNA 調控網絡及其應用基礎。2011 年以來，圍繞“肝癌功能基因組學”，研究參與肝癌相關的轉錄調控及轉錄后調控的重要RNA、蛋白分子的功能及臨床意義，取得了一系列原創性科研成果。

代表性論著：

1. Zhe Li^#, Jiwei Zhang^#, Xinyang Liu^#, Shengli Li, Qifeng Wang, Di Chen, Zhixiang Hu, Tao Yu, Jie Ding, Jinjun Li, Ming Yao, Jia Fan, Shenglin Huang, Qiang Gao^*, Yingjun Zhao^*, Xianghuo He^*. The LINC01138 drives malignancies via activating arginine methyltransferase 5 in hepatocellular carcinoma. Nature Communications, 2018 Apr 20; 9:1572. 10.1038/s41467-018-04006-0.
2. Jiwei Zhang^#, Zhe Li^#, Longzi Liu^#, Qifeng Wang, Shengli Li, Di Chen, Zhixiang Hu, Tao Yu, Jie Ding, Jinjun Li, Ming Yao, Shenglin Huang, Yingjun Zhao^*, Xianghuo He^*. Long Noncoding RNA TSLNC8 Is a Tumor Suppressor That Inactivates the Interleukin-6/STAT3 Signaling Pathway. Long noncoding RNA TSLNC8 is a tumor suppressor that inactivates the interleukin-6/STAT3 signaling pathway. Hepatology, 2018; 67(1):171-187.
3. Tao Yu^#, Yingjun Zhao^#, Zhixiang Hu, Jing Li, Dandan Chu, Jiwei Zhang, Zhe Li, Bing Chen, Xiao Zhang, Hongyu Pan, Shengli Li, Hechun Lin, Lei Liu, Mingxia Yan, Xianghuo He^*, Ming Yao^*. MetaLnc9 facilitates lung cancer metastasis via a PGK1-Activated AKT/mTOR pathway. Cancer Research, 2017; 77(21):5782-5794.
4. Qiu Zhaoping^#, Guo Weijie^#, Wang Qifeng^#, Chen Zhiao, Huang Shenglin, Zhao Fangyu, Yao Ming, Zhao Yingjun^*, He Xianghuo^*. MicroRNA-124 reduces the pentose phosphate pathway and proliferation by targeting PRPS1 and RPIA mRNAs in human colorectal cancer cells. Gastroenterology, 2015; 149(6):1587-1598.e11.
5. Guo Weijie^#, Qiu Zhaoping^#, Wang Zhichao^#, Wang Qifeng, Tan Ning, Chen Taoyang, Chen Zhiao, Huang Shenglin, Gu Jianren, Li Jinjun, Yao Ming, Zhao Yingjun^*, He Xianghuo^*. MiR-199a-5p is negatively associated with malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer. Hepatology, 2015; 62(4):1132-1144.
6. Gao Qiang^#, Zhao Ying-Jun^#, Wang Xiao-Ying^#, Guo Wei-Jie, Gao Song, Wei Lin, Shi Jie-Yi, Shi Guo-Ming, Wang Zhi-Chao, Zhang Yuan-Nv, Shi Ying-Hong, Ding Jie, Ding Zhen-Bin, Ke Ai-Wu, Dai Zhi, Wu Fei-Zhen, Wang Hui, Qiu Zhao-Ping, Chen Zhi-Ao, Zhang Zhen-Feng, Qiu Shuang-Jian, Zhou Jian^*, He Xiang-Huo^*, Fan Jia^*. Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients. Gastroenterology, 2014; 146(5): 1397-1407.
7. Gao Qiang^#, Zhao Ying-Jun^#, Wang Xiao-Ying^#, Qiu Shuang-Jian, Shi Ying-Hong, Sun Jian, Yi Yong, Shi Jie-Yi, Shi Guo-Ming, Ding Zhen-Bin, Xiao Yong-Sheng, Zhao Zhong-Hua, Zhou Jian^*, He Xiang-Huo^*, Fan Jia^*. CXCR6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma. Cancer Research, 2012; 72(14):3546-3556.
8. Zhao Yingjun^#, Wang Xiaoying^#, Wang Tao, Hu Xin, Hui Xin, Yan Mingxia, Gao Qiang, Chen Taoyang, Li Jinjun, Yao Ming, Wan Dafang, Gu Jianren^*, Fan Jia^*, He Xianghuo^*. Acetylcholinesterase, a key prognostic predictor for hepatocellular carcinoma, suppresses cell growth and induces chemosensitization. Hepatology, 2011; 53(2):493-503.